P

Inventor

MUSICKI BRANISLAV

FR24 patents
⚠️ This page may combine multiple inventors who share the name “MUSICKI BRANISLAV”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.

GALDERMA RES & DEV

14 patents
US9650337B2May 16, 2017

Method of synthesising 4-piperidin-4-yl-benzene-1,3-diol and the salts of same and novel compound tert-butyl 4-(2,4-dihydroxy-phenyl)-4-hydroxy-piperidine-1-carboxylate

GALDERMA RES & DEV3 citations72
US10246440B2Apr 2, 2019

Indazole sulfonamide derivatives as inverse agonists of retinoid-related orphan receptor gamma (ROR γ (T))

GALDERMA RES & DEV2 citations71
US9090596B2Jul 28, 2015

Disubstituted 3,4-diamino-3-cyclobutene-1,2-dione compounds for use in the treatment of chemokine-mediated pathologies

GALDERMA RES & DEV3 citations60
US10752617B2Aug 25, 2020

Indazole sulfonamide derivatives as inverse agonists of retinoid-related orphan receptor gamma (ROR gamma (T))

GALDERMA RES & DEV0 citations51
US10618890B2Apr 14, 2020

Benzimidazole sulfonamide derivatives as inverse agonists of retinoid-related orphan receptor gamma (ROR gamma (T))

GALDERMA RES & DEV0 citations51
US10550110B2Feb 4, 2020

Tetrahydroquinoline sulfonamide derivatives as inverse agonists of retinoid-related orphan receptor gamma (ROR gamma (t))

GALDERMA RES & DEV0 citations51
US9580412B2Feb 28, 2017

Disubstituted 3,4-diamino-3-cyclobutene-1,2-dione compounds for use in the treatment of chemokine-mediated diseases

GALDERMA RES & DEV1 citations49
US9526732B2Dec 27, 2016

Disubstituted 3,4-diamino-3-cyclobutene-1,2-dione compounds for use in the treatment of chemokine-mediated pathologies

GALDERMA RES & DEV1 citations49
US9415039B2Aug 16, 2016

Disubstituted 3,4-diamino-3-cyclobutene-1,2-dione compounds for use in the treatment of chemokine-mediated diseases

GALDERMA RES & DEV0 citations49
US9120772B2Sep 1, 2015

Disubstituted 3,4-diamino-3-cyclobutene-1,2-dione compounds for use in the treatment of chemokine-mediated diseases

GALDERMA RES & DEV0 citations49
US10647706B2May 12, 2020

Chemokine CXCR1 and CXCR2 receptor antagonist compounds, and use thereof in the treatment of chemokine-mediated pathologies

GALDERMA RES & DEV0 citations48
US10287278B2May 14, 2019

Chemokine CXCR1 and CXCR2 receptor antagonist compounds, and use thereof in the treatment of chemokine-mediated pathologies

GALDERMA RES & DEV0 citations48
US9388149B2Jul 12, 2016

Disubstituted 3,4-diamino-3-cyclobutene-1,2-dione compounds for use in the treatment of chemokine-mediated diseases

GALDERMA RES & DEV1 citations46
US10457637B2Oct 29, 2019

Benzenesulfonamide derivatives as inverse agonists of retinoid-related orphan receptor gamma (RORγ(T))

GALDERMA RES & DEV0 citations40

AVENTIS PHARMA SA

6 patents

NOVEXEL

1 patent

ASZODI JOSEPH

1 patent

MUSICKI BRANISLAV

1 patent

Galderma Holding SA

1 patent